Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Shapsis

Gastroenterology Brooklyn, NY Medical Doctor

NPI 1952325599 CMS profile 270595

239 Court St, Brooklyn, NY 11201

Open in the dashboard

General payments

$75,947

790 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Shapsis of Brooklyn, NY is reported in the CMS Open Payments database as having received $75,947 across 790 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,283 115
2024 General $5,455 141
2023 General $5,587 101
2022 General $12,948 123
2021 General $13,988 133
2020 General $7,043 63
2019 General $21,643 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Shapsis
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Alexander Shapsis were reported at $9,283. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Alexander Shapsis Gastroenterology median Middle half National median
2019 $21,643 $417 $126–$1,100 $163
2020 $7,043 $224 $74–$624 $114
2021 $13,988 $352 $106–$1,054 $132
2022 $12,948 $448 $129–$1,270 $149
2023 $5,587 $533 $150–$1,390 $160
2024 $5,455 $605 $160–$1,606 $164
2025 $9,283 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $35,424 220 payments
  2. Gilead Sciences, Inc. $27,976 70 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,890 114 payments
  4. Apollo Endosurgery US Inc $1,588 11 payments
  5. Romark Laboratories, LC $1,132 3 payments
  6. Janssen Biotech, Inc. $811 32 payments
  7. QOL Medical, LLC $763 36 payments
  8. Celgene Corporation $758 50 payments
  9. Ardelyx, Inc. $610 22 payments
  10. Pfizer Inc. $558 34 payments
  11. Other $4,437 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51,970 28 payments
  2. Food and Beverage $16,594 744 payments
  3. Travel and Lodging $3,940 14 payments
  4. Consulting Fee $3,360 2 payments
  5. Education $83 2 payments
Products named General payments · program years 2019–2025
  1. CREON $17,395 76 payments
  2. Epclusa $12,310 23 payments
  3. MAVYRET $6,329 69 payments
  4. OverStitch Endoscopic Suturing System $1,588 11 payments
  5. XIFAXAN $1,581 99 payments
  6. ALINIA Gastroenterology $1,132 3 payments
  7. ALINIA Gastroenterology $1,132 3 payments
  8. ALINIA Gastroenterology $1,132 3 payments
  9. ZEPOSIA $763 50 payments
  10. HUMIRA $746 38 payments
  11. Other $10,975 530 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

3,771

Median for Gastroenterology: 569

Drug cost

$2,255,745

Median for Gastroenterology: $104,976

Branded share of claims

58.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 427 $871,381
Zenpep Lipase/Protease/Amylase Brand 156 $466,166
Linzess Linaclotide Brand 378 $196,909
Xifaxan Rifaximin Brand 70 $171,824
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 67 $120,677
Ibsrela Tenapanor Hcl Brand 65 $114,826
Mounjaro Tirzepatide Brand 85 $84,195
Dexlansoprazole Dr Dexlansoprazole Brand 314 $52,115
Ozempic Semaglutide Brand 49 $44,910
Trulance Plecanatide Brand 51 $28,732

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$184,923

Medicare's payments for the services billed

Medicare patients

452

Average age 73

Services billed

3,083

288 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 62%
Ischemic heart disease 52%
Depression 41%
Heart failure 25%
Chronic kidney disease 25%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$342 14 —
ZEPOSIA
$251 — —
IBSRELA
$228 65 —
LINZESS
$196 378 —
CREON
$192 427 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

790 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record